Cargando…
Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)
BACKGROUND: Patients with locally advanced bladder cancer (cT3/4 cN0/N+ cM0) have a poor prognosis despite radical surgical therapy and perioperative chemotherapy. Preliminary data suggest that the combination of radiation and immunotherapy does not lead to excess toxicity and may have synergistic (...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942254/ https://www.ncbi.nlm.nih.gov/pubmed/31900121 http://dx.doi.org/10.1186/s12885-019-6503-6 |
_version_ | 1783484664539774976 |
---|---|
author | Schmid, Sebastian C. Koll, Florestan J. Rödel, Claus Maisch, Philipp Sauter, Andreas Beckert, Franziska Seitz, Anna Kübler, Hubert Flentje, Michael Chun, Felix Combs, Stephanie E. Schiller, Kilian Gschwend, Jürgen E. Retz, Margitta |
author_facet | Schmid, Sebastian C. Koll, Florestan J. Rödel, Claus Maisch, Philipp Sauter, Andreas Beckert, Franziska Seitz, Anna Kübler, Hubert Flentje, Michael Chun, Felix Combs, Stephanie E. Schiller, Kilian Gschwend, Jürgen E. Retz, Margitta |
author_sort | Schmid, Sebastian C. |
collection | PubMed |
description | BACKGROUND: Patients with locally advanced bladder cancer (cT3/4 cN0/N+ cM0) have a poor prognosis despite radical surgical therapy and perioperative chemotherapy. Preliminary data suggest that the combination of radiation and immunotherapy does not lead to excess toxicity and may have synergistic (abscopal) anti-tumor effects. We hypothesize that the combined preoperative application of the PD-1 checkpoint-inhibitor Nivolumab with concomitant radiation therapy of the bladder and pelvic region followed by radical cystectomy with standardized lymphadenectomy is safe and feasible and might improve outcome for patients with locally advanced bladder cancer. METHODS: Study design: “RACE IT” (AUO AB 65/18) is an investigator initiated, prospective, multicenter, open, single arm phase II trial sponsored by Technical University Munich. Study drug and funding are provided by the company Bristol-Myers Squibb. Study treatment: Patients will receive Nivolumab 240 mg i.v. every 2 weeks for 4 cycles preoperatively with concomitant radiation therapy of bladder and pelvic region (max. 50.4 Gy). Radical cystectomy with standardized bilateral pelvic lymphadenectomy will be performed between week 11–15. Primary endpoint: Rate of patients with completed treatment consisting of radio-immunotherapy and radical cystectomy at the end of week 15. Secondary endpoints: Acute and late toxicity, therapy response and survival (1 year follow up). Main inclusion criteria: Patients with histologically confirmed, locally advanced bladder cancer (cT3/4, cN0/N+), who are ineligible for neoadjuvant, cisplatin-based chemotherapy or who refuse neoadjuvant chemotherapy. Main exclusion criteria: Patients with metastatic disease (lymph node metastasis outside pelvis or distant metastasis) or previous chemo-, immune- or radiation therapy. Planned sample size: 33 patients, interim analysis after 11 patients. DISCUSSION: This trial aims to evaluate the safety and feasibility of the combined approach of preoperative PD-1 checkpoint-inhibitor therapy with concomitant radiation of bladder and pelvic region followed by radical cystectomy. The secondary objectives of therapy response and survival are thought to provide preliminary data for further clinical evaluation after successful completion of this trial. Recruitment has started in February 2019. TRIAL REGISTRATION: Protocol Code RACE IT: AB 65/18; EudraCT: 2018–001823-38; Clinicaltrials.gov: NCT03529890; Date of registration: 27 June 2018. |
format | Online Article Text |
id | pubmed-6942254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69422542020-01-07 Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT) Schmid, Sebastian C. Koll, Florestan J. Rödel, Claus Maisch, Philipp Sauter, Andreas Beckert, Franziska Seitz, Anna Kübler, Hubert Flentje, Michael Chun, Felix Combs, Stephanie E. Schiller, Kilian Gschwend, Jürgen E. Retz, Margitta BMC Cancer Study Protocol BACKGROUND: Patients with locally advanced bladder cancer (cT3/4 cN0/N+ cM0) have a poor prognosis despite radical surgical therapy and perioperative chemotherapy. Preliminary data suggest that the combination of radiation and immunotherapy does not lead to excess toxicity and may have synergistic (abscopal) anti-tumor effects. We hypothesize that the combined preoperative application of the PD-1 checkpoint-inhibitor Nivolumab with concomitant radiation therapy of the bladder and pelvic region followed by radical cystectomy with standardized lymphadenectomy is safe and feasible and might improve outcome for patients with locally advanced bladder cancer. METHODS: Study design: “RACE IT” (AUO AB 65/18) is an investigator initiated, prospective, multicenter, open, single arm phase II trial sponsored by Technical University Munich. Study drug and funding are provided by the company Bristol-Myers Squibb. Study treatment: Patients will receive Nivolumab 240 mg i.v. every 2 weeks for 4 cycles preoperatively with concomitant radiation therapy of bladder and pelvic region (max. 50.4 Gy). Radical cystectomy with standardized bilateral pelvic lymphadenectomy will be performed between week 11–15. Primary endpoint: Rate of patients with completed treatment consisting of radio-immunotherapy and radical cystectomy at the end of week 15. Secondary endpoints: Acute and late toxicity, therapy response and survival (1 year follow up). Main inclusion criteria: Patients with histologically confirmed, locally advanced bladder cancer (cT3/4, cN0/N+), who are ineligible for neoadjuvant, cisplatin-based chemotherapy or who refuse neoadjuvant chemotherapy. Main exclusion criteria: Patients with metastatic disease (lymph node metastasis outside pelvis or distant metastasis) or previous chemo-, immune- or radiation therapy. Planned sample size: 33 patients, interim analysis after 11 patients. DISCUSSION: This trial aims to evaluate the safety and feasibility of the combined approach of preoperative PD-1 checkpoint-inhibitor therapy with concomitant radiation of bladder and pelvic region followed by radical cystectomy. The secondary objectives of therapy response and survival are thought to provide preliminary data for further clinical evaluation after successful completion of this trial. Recruitment has started in February 2019. TRIAL REGISTRATION: Protocol Code RACE IT: AB 65/18; EudraCT: 2018–001823-38; Clinicaltrials.gov: NCT03529890; Date of registration: 27 June 2018. BioMed Central 2020-01-03 /pmc/articles/PMC6942254/ /pubmed/31900121 http://dx.doi.org/10.1186/s12885-019-6503-6 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Schmid, Sebastian C. Koll, Florestan J. Rödel, Claus Maisch, Philipp Sauter, Andreas Beckert, Franziska Seitz, Anna Kübler, Hubert Flentje, Michael Chun, Felix Combs, Stephanie E. Schiller, Kilian Gschwend, Jürgen E. Retz, Margitta Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT) |
title | Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT) |
title_full | Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT) |
title_fullStr | Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT) |
title_full_unstemmed | Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT) |
title_short | Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT) |
title_sort | radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase ii trial (race it) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942254/ https://www.ncbi.nlm.nih.gov/pubmed/31900121 http://dx.doi.org/10.1186/s12885-019-6503-6 |
work_keys_str_mv | AT schmidsebastianc radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT kollflorestanj radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT rodelclaus radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT maischphilipp radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT sauterandreas radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT beckertfranziska radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT seitzanna radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT kublerhubert radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT flentjemichael radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT chunfelix radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT combsstephaniee radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT schillerkilian radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT gschwendjurgene radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit AT retzmargitta radiationtherapybeforeradicalcystectomycombinedwithimmunotherapyinlocallyadvancedbladdercancerstudyprotocolofaprospectivesinglearmmulticenterphaseiitrialraceit |